Table II.
Summary of randomized controlled trial research to treat primary central nervous system lymphoma in the elderly.
| First author, year | Treatment protocol | Phase | Patients, n | Median age, years | Median OS, months or % | Median PFS, months or % | (Refs.) |
|---|---|---|---|---|---|---|---|
| Omuro, 2007 | HD-MTX + TMZ | II | 23 | 68 | 35 | 8 | (10) |
| Fritsch, 2017 | R + HD-MTX + procarbazine + lomustine (R-MPL)/RMP→ procarbazine maintenance | II | 107 | 73 | 2-year OS 47% | 2-year PFS 37.3% | (59) |
| Hoang-Xuan, 2003 | HD-MTX + lomustine + procarbazine + methylprednisolone + IT MTX and cytarabine | II | 50 | 72 | 14.3 | 1-year PFS 40% | (60) |
| Illerhaus, 2009 | HD-MTX + procarbazine + CCNU | II | 29 | 70 | 15.4 | 5.9 | (61) |
| Roth, 2012 | HD-MTX-based chemotherapy | III | 126 | ≥70 | 12.5 | 4 | (62) |
| Olivier, 2014 | HD-MTX + VDS + PRED + idarubicin | I | 35 | 65 | 19 | 13 | (63) |
| Omuro, 2015 | HD-MTX + TMZ vs. HD-MTX + PCZ + VCR → cytarabine (MPV-A) | II | 48 47 | 73 72 | 14 31 | 6.1 9.5 | (64) |
| Pulczynski, 2015 | HD-MTX + IT liposomal cytarabine→ TMZ maintenance | II | 27 | 70 | 2-year OS 55.6% | 2-year PFS 44.4% | (65) |
OS, overall survival; PFS, progression-free survival; HD-MTX, high-dose methotrexate; TMZ, temozolomide; R, rituximab; IT, intrathecal injection therapy; VDS, vindesine; PRED, prednisone; PCZ, procarbazine; VCR, vincristine.